Evotec
Manasa Kalya is an accomplished professional in the field of personalized medicine and computational biology, currently serving as an Assistant Professor at Amsterdam UMC since August 2024, focusing on innovative diagnostics and therapies for rare genetic disorders. Prior experience includes a Research Associate position at Evotec, along with completing a Ph.D. in Medical Bioinformatics at The University of Göttingen. Manasa has held various research roles, including Associate Research Fellow at the Marie Curie Alumni Association and Research Developer at geneXplain. Previous scientific research experience includes work at the National Institute of Mental Health and Neuro Sciences and the National Centre for Biological Sciences, contributing to key projects in cell line generation and gene prioritization for genetic disorders. Educational background includes a Master’s degree from Visvesvaraya Technological University and a Bachelor's degree from Siddaganga Institute of Technology. Manasa also holds a Professional Certification in Machine Learning and AI from the Massachusetts Institute of Technology.
Previous companies
This person is not in any teams
This person is not in any offices
Evotec
5 followers
Evotec AG is a drug discovery and development company. The Company operates through two segments. The EVT Execute segment provides standalone drug discover services on a typical fee-for-service basis or integrated drug discovery collaborations on partners' target through a range of commercial structures, including research fees, milestones and/or royalties. The EVT Innovate segment develops drug discovery programs and assets, both internally or through academic collaborations. The Company seeks to partner these into collaborations in return for upfront payments, ongoing research payments. It consists of all partnerships derived from its internally developed assets and platforms and its participations in certain companies. It includes clinical initiations and progress of clinical pipeline within partnerships; expansion of academic BRIDGE network; research and development (R&D) progress with CureX/Target X initiatives, and focuses on induced pluripotent stem cells (iPSC) platform.